# US 2020/0002667 A1 · Biomatrix scaffolds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002667 A1
- Document ID: US20200002667A1
- Status: Published application
- Kind: A1
- Application number: 16/274,020
- Filed: 2019-02-12
- Published: 2020-01-02
- Earliest claimed: 2010-07-02
- Assignees: The University of North Carolina at Chapel Hill
- Applicants: The University of North Carolina at Chapel Hill
- Inventors: Yunfang Wang; Lola Cynthia McAdams Reid; Mitsuo Yamauchi; Cai-Bin Cui; Andrew Zhuang Wang; Michael Edward Werner
- Web page: https://patentgrep.com/patent/US20200002667A1

## CPC

- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- A61L 27/24: Collagen
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/3683: {subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment}
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- C12N 5/067: {Hepatocytes}
- C12N 5/0671: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61L 2430/28: for liver reconstruction
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2500/36: Lipids
- C12N 2501/20: Cytokines; Chemokines
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/14: from hepatocytes
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A biomatrix scaffold produced by a method comprising:
a) perfusing the biological tissue or homogenizing the biological tissue with a first medium, wherein the osmolality of said first medium is from about 250 mOsm/kg to about 350 mOsm/kg and said first medium is serum free and at neutral pH; then
b) perfusing the biological tissue or extracting the homogenate of step (a) with a delipidating buffer comprising lipases and/or detergents in said first medium; wherein the detergents do not comprise sodium dodecyl sulfate or Triton X-100; then
c) perfusing the tissue or extracting the homogenate of step (b) with a buffer comprising a pH and a salt concentration, wherein the pH and the salt concentration keep a plurality of collagens in the biological tissue in an insoluble state; then
d) rinsing the tissue or homogenate of step (c) with a second medium that is at neutral pH, is serum-free and has an osomolality from about 250 mOsm/kg to about 350 mOsm/kg;
thereby producing an intact or homogenized biomatrix scaffold from the biological tissue, said biomatrix scaffold comprising at least 95% of the collagens and most collagen-associated matrix components and matrix bound growth factors, hormones and cytokines of the biological tissue.

### Claim 18 (depends on 17)

The biomatrix scaffold according to claim 17, comprising collagens, fibronectins, laminins, nidogen/entactin, elastin, proteogylcans, glycosaminoglycans, growth factors, cytokines or any combination thereof, all being part of the biomatrix scaffold.

### Claim 19 (depends on 17)

A method of producing a cell culture, comprising:
a) contacting the biomatrix scaffold of claim 17 with cell culture medium in a culture apparatus; and
b) seeding the biomatrix scaffold of step (a) with cells, thereby producing a cell culture.

### Claim 20 (depends on 17)

A method of producing a cell culture, comprising:
a) freezing the biomatrix scaffold of claim 17;
b) preparing a frozen section from the biomatrix scaffold of step (a) as a cell culture substratum;
c) contacting the cell culture substratum of step (b) with cell culture medium in a culture apparatus; and
d) seeding the cell culture substratum of step (c) with cells, thereby producing a cell culture.

### Claim 21 (depends on 17)

A method of producing a cell culture, comprising:
a) grinding the biomatrix scaffold of claim 17 to a powder;
b) coating at least part of a culture apparatus with the powder of step (a) to produce a cell culture substratum;
c) contacting the cell culture substratum of (b) with cell culture medium in the culture apparatus; and
d) seeding the cell culture substratum of (c) with cells, thereby producing a cell culture.

### Claim 22 (depends on 21)

The method of claim 21, wherein the grinding of the biomatrix scaffold is carried out in a freezer mill at or near liquid nitrogen temperatures.

### Claim 23 (depends on 19)

The method of claim 19, wherein the cell culture medium comprises at least one of the constituents present in interstitial fluid, wherein the osmolality of said medium is from about 250 mOsm/kg to about 350 mOsm/kg and wherein said medium is serum free.

### Claim 24 (depends on 23)

The method of claim 23, wherein the medium is RPMI-1640.

### Claim 25 (depends on 19)

The method of claim 19, wherein the cells are of the same type as the cells of the biological tissue used to make the biomatrix scaffold.

### Claim 26 (depends on 19)

The method of claim 19, wherein the cells are selected from the group consisting of embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, determined stem cells, perinatal stem cells, amniotic fluid-derived stem cells (AFSCs), mesenchymal stem cells (MSCs) from any source, committed progenitors or adult cells of any tissue type, mature cells, normal cells, diseased cells, tumor cells and any combination thereof.

### Claim 27 (depends on 19)

The method of claim 19, wherein the cells are selected from the group consisting of liver cells, parenchymal cells, stellate cells, endothelial cells, hepatocytes, cholangiocytes, biliary tree cells that are not cholangiocytes and pancreatic cells.

### Claim at position 13

-29. (canceled)

### Claim 30 (depends on 19)

A cell culture produced by the method of claim 19.

### Claim 31 (depends on 19)

A method of enhancing and accelerating differentiation of stem cells and/or progenitors to mature cells, comprising producing a cell culture according to the method of claim 19, wherein the cells are stem cells and the cell culture medium is formulated for mature cells, thereby enhancing and accelerating differentiation of stem cells and/or progenitors to mature cells.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cells are adult cells of any type or are stem cells or progenitors selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, germ layer stem cells, determined stem cells, perinatal stem cells, amniotic fluid-derived stem cells, mesenchymal stem cells, transit amplifying cells or committed progenitors of any tissue type.

### Claim 33 (depends on 31)

The method of claim 31, wherein the cell culture medium is selected from the group consisting of RPMI 1640, DME/F12, DME, F12, Waymouth's, and William's medium.

### Claim at position 18

-39. (canceled)

### Claim 40 (depends on 17)

A method of producing virus particles of a lineage dependent virus, comprising:
a)) contacting the biomatrix scaffold of claim 17 with cell culture medium in a culture apparatus;
b) seeding the biomatrix scaffold of (a) with cells of a type and lineage stage that can be infected with the lineage dependent virus;
c) infecting the cells of (b) with the lineage dependent virus;
d) maintaining the infected cells on the biomatrix scaffold under culture conditions; and
e) collecting virus particles produced in the infected cells,
thereby producing virus particles of the lineage dependent virus.

### Claim 41 (depends on 40)

The method of claim 40, wherein the lineage dependent virus is selected from the group consisting of hepatitis C virus, hepatitis B virus, noro virus, and human papilloma virus.

### Claim 42 (depends on 17)

A method of producing an organoid formed by recellularization of a biomatrix scaffold, comprising:
a)) contacting the biomatrix scaffold of claim 17 with cell culture medium in a culture apparatus;
b) seeding the biomatrix scaffold of (a) with cells of the same tissue type as the biological tissue used to prepare the biomatrix scaffold; and
c) maintaining the cells on the biomatrix scaffold under culture conditions, whereby organoids form from the cells,
thereby producing an organoid formed by recellularization of the biomatrix scaffold.

### Claim 43 (depends on 42)

The method of claim 42, further comprising the step of contacting the organoid with a subject, for use as an assist device.

### Claim 44 (depends on 42)

The method of claim 42, wherein the cells are liver cells.

### Claim at position 24

-46. (canceled)

### Claim 47 (depends on 20)

The method of claim 20, wherein the cell culture-medium comprises at least one of the constituents present in interstitial fluid, wherein the osmolality of said medium is from about 250 mOsm/kg to about 350 mOsm/kg and wherein said medium is serum free.

### Claim 48 (depends on 20)

The method of method of claim 20, wherein the cells are of the same type as the cells of the biological tissue used to make the biomatrix scaffold.

### Claim 49 (depends on 20)

The method of claim 20, wherein the cells are selected from the group consisting of embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, determined stem cells, perinatal stem cells, amniotic fluid-derived stem cells (AFSCs), mesenchymal stem cells (MSCs) from any source, committed progenitors or adult cells of any tissue type, mature cells, normal cells, diseased cells, tumor cells and any combination thereof.

### Claim 50 (depends on 20)

The method of claim 20, wherein the cells are selected from the group consisting of liver cells, parenchymal cells, stellate cells, endothelial cells, hepatocytes, cholangiocytes, biliary tree cells that are not cholangiocytes and pancreatic cells.

### Claim 51 (depends on 20)

A cell culture produced by the method of claim 20.

### Claim 52 (depends on 20)

A method of enhancing and accelerating differentiation of stem cells and/or progenitors to mature cells, comprising producing a cell culture according to the method of claim 20, wherein the cells are stem cells and the cell culture medium is formulated for mature cells, thereby enhancing and accelerating differentiation of stem cells and/or progenitors to mature cells.

### Claim 53 (depends on 52)

The method of claim 52, wherein the cells are adult cells of any type or are stem cells or progenitors selected from the group consisting of embryonic stem cells, induced pluripotent stem cells, germ layer stem cells, determined stem cells, perinatal stem cells, amniotic fluid-derived stem cells, mesenchymal stem cells, transit amplifying cells or committed progenitors of any tissue type.

### Claim 54 (depends on 52)

The method of claim 52, wherein the cell culture medium is selected from the group consisting of RPMI 1640, DME/F12, DME, F12, Waymouth's, and William's medium.

### Claim 55 (depends on 17)

The method of claim 17, wherein the pH is neutral, and the salt concentration is from about 2.0 M to about 5.0 M NaCl.
